title: [Study of administration times and clinical efficacy of carbapenems in the treatment of moderate community-acquired bacterial pneumonia].
abstract: The half-lives of carbapenems are about 1 hour. It was expected that increasing the daily frequency of administration would improve the clinical effects. We therefore studied the clinical effects of increasing the daily administration frequency of meropenem in the treatment of community-acquired bacterial pneumonia. The subjects were patients with moderate community-acquired bacterial pneumonia who were aged less than 75 years. They were divided into a BID group (28 patients receiving 0.5 g morning and evening) and a TID group (27 patients receiving 0.25 g in the morning and about midday, and 0.5 g in the evening), and the clinical effects were reviewed prospectively. Clinical efficacy on the third day was 78.6% in the BID group and 85.2% in the TID group, and over-all clinical efficacy was 89.3% in the BID group and 88.9% in the TID group. Administration periods were 12.8 +/- 4.2 days in the BID group and 10.9 +/- 3.4 days in the TID group. These results show no statistically significant difference, and suggest that the excellent clinical effect of administration of MEPM 0.5 g twice a day on moderate community-acquired bacterial pneumonia is not improved by administration three times a day.
authors.affiliation: Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School Kawasaki Hospital.
authors.forename: Niro
authors.initials: N
authors.lastname: Okimoto
authors.forename: Kenji
authors.initials: K
authors.lastname: Yamato
authors.forename: Takeyuki
authors.initials: T
authors.lastname: Kurihara
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Honda
authors.forename: Kohichi
authors.initials: K
authors.lastname: Osaki
authors.forename: Naoko
authors.initials: N
authors.lastname: Asaoka
authors.forename: Kazue
authors.initials: K
authors.lastname: Fujita
authors.forename: Hideo
authors.initials: H
authors.lastname: Ohba
mesh_terms: D000328:Adult; D000368:Aged; D015780:Carbapenems / Q000008:administration & dosage / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000188:drug therapy*; D011446:Prospective Studies
chemical_list: D015780:Carbapenems